Assessment of sub-dividable, extemporaneously prepared suspensions to support early phase clinical trials
- Lumley-Wood, P.
- Pearce, H.
- Newcomb, C.
- Porreca, J.
- Morgan, S.
Journal of Pharmacy and Pharmacology 62(10):p 1405-1406, October 2010.
Abstract
- Optimising the rapid and flexible delivery of clinical doses, Pfizer employ Extemporaneous Preparation (EP) as a standard approach to Phase I dose preparation. This abstract describes the analysis of suspension homogeneity as an example of EP process improvement.
Copyright © 2010 John Wiley & Sons, Inc.